Home
Class 12
BIOLOGY
(i) What is gene therapy? Name the first...

(i) What is gene therapy? Name the first clinical case where it was used.
(ii) Why is the introduction of genetically engineered lymphocytes into ADA deficiency patient not a permanent cure? Suggest a possible permanent cure.

Promotional Banner

Topper's Solved these Questions

  • SAMPLE QUESTION PAPER 5

    ICSE|Exercise PART II (SECTION B) All the questions are compulsory.|9 Videos

  • SAMPLE QUESTION PAPER 4

    ICSE|Exercise PART II|33 Videos

  • SELF ASSESSMENT PAPER 05

    ICSE|Exercise Part-II (Section-C)|8 Videos

Similar Questions

Explore conceptually related problems

Why is the introduction of genetically engineered lymphocytes into a ADA deficiency patient not a permanent cure ? Suggest a possible permanent cure.

Assertion: In gene therapy of SCID, a patient requires periodic infusion of genetically engineered lymphocytes Reason :If the ADA gene is introducted into cells at early embryonic stage, it could be a permanent cure

What is meant by ADA deficiency? How is gene therapy a solution to this problem? Why is it not a permanent cure?

Write the function of adenosine deaminase enzyme. State the cause of ADA deficiency in humans. Mention a possible permanent cure for a ADA deficiency patient.

Introduction of ADA gene into bone marrow cells at embryonic stages may act as a permanent cure is which of the following disease ?

Assertion: ADA deficiency can not be cured permanently by gene therapy Reason :The genetically engineered lymphocytes are immortal only in culture conditions

(a) Name the deficiency for which first clinical gene therapy was given. (b) Mention the cause of and one cure for this deficiency.

(a) What is plasmid? (b) What is meant by ADA deficiency ? How is gene therapy a solution to this problem ? Why is it not a permanent cure ?

What is the permanent cure of adenosine deaminase (ADA) deficiency in children ?

Assertion : The first clinical gene for ADA therapy was given to cure SCID Reason : The normal gene was delivered into the patient's cell using retroviral vector